Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan, +30

Nature Cancer

Lymphoid NeoplasiaCancer ImmunosurveillancePd-l1 ExpressionSolid TumorsMedicine +7

Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation

Thierry de Baère, Jean Palussière, Anne Aupérin, +10

Radiology

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier, +19

The Lancet Oncology

Surgical OncologyAdvanced Ewing SarcomaMedicineMetronomic TherapyPharmacotherapy +3

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido, +17

Nature Medicine

Lymphoid NeoplasiaPembrosarc Trial CohortMedicineSoft-tissue SarcomasImmunology +5

Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

Maud Toulmonde, Marina Pulido, Isabelle Ray‐Coquard, +20

The Lancet Oncology

OncologyCombination ChemotherapyMetronomic TherapyProgressive Desmoid TumoursPharmacotherapy +6

Soft-Tissue Sarcomas: Assessment of MRI Features Correlating with Histologic Grade and Patient Outcome

Amandine Crombé, Pierre-Jean Marcellin, Xavier Buy, +5

Radiology

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

Axel Le Cesne, Perrine Marec‐Bérard, Jean‐Yves Blay, +13

European Journal of Cancer

MedicineApoptosisCell DeathPathologyAdvanced Osteosarcomas +6

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, +11

Clinical Cancer Research

Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors

Nathalie Lassau, Julia Bonastre, Michèle Kind, +20

Investigative Radiology

T₂‐based MRI Delta‐radiomics improve response prediction in soft‐tissue sarcomas treated by neoadjuvant chemotherapy.

Amandine Crombé, C. Périer, Michèle Kind, +5

Journal of Magnetic Resonance Imaging